Raveron (a European pharmaceutical consisting of swine prostate extract and m-creosal) was studied in vivo in female mongrel dogs and in vitro bladder studies were conducted on male New Zealand rabbits. Intravenous administration of raveron reduced both the passive and active pressure in dog detrusor in vivo. It did not act in a dose dependent fashion. Chronic treatment with raveron for three to four months caused changes in rabbits with vesical neck obstruction. An increase in contractility along with a reduced rate of increase in passive force (measurement of bladder stiffness) was observed in relation to obstructed rabbits without treatment. Parallel morphological changes were also observed in this group, consisting of increased muscular hypertrophy, decreased bladder wall thickness and reduced collagen content (readings taken from Masson-Trichrome sections). No influence was observed with bladder specimens from rabbits with six to eight week vesical obstruction or normals that received treatment. In vitro dose response studies showed that a 3.3% dose of raveron significantly reduced passive force in two groups (treated normals and treated rabbits with six to eight week vesical obstruction). Pharmacology studies with potassium chloride and acetylcholine suggest that raveron acts as a calcium antagonist by blocking the influx of extracellular calcium.
ASJC Scopus subject areas